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ABSTRACT 
The patenting of biological resources collected from 
indigenous groups has become a controversial trend. Two U.S. 
patents in particular, one claiming a cell-line from a 26-year old 
Guayami woman and one claiming a leukemia virus from a 
Hagahai man in Papua New Guinea, demonstrate just how volatile 
this issue has become. This iBrief examines how, in light of such 
“ethically questionable” patents, the U.S. Patent Office has failed 
to implement any procedures to identify or curb patent applications 
involving indigenous peoples.
INTRODUCTION 
¶1 The ethical debate surrounding the patenting of biological material 
has reached new levels now that scientists and researchers have been 
gathering and patenting DNA samples from indigenous populations around 
the world. The debate raises numerous issues. For instance, will the data, 
which to date has revealed information on diseases such as leukemia and 
AIDS, stigmatize or create outsider prejudice towards indigenous 
populations? Have these isolated groups, which may speak different 
languages than researchers and scientists, given informed consent to the 
researchers and scientists? Should indigenous populations receive 
compensation for use of their genetic material? To what extent do these 
groups control or own their genetic material, which to many groups holds 
very sacred and religious significance? Finally, what are the collective 
rights of the tribe, which often defiantly oppose the testing, versus the rights 
of individual tribe members who wish to partake in the biological research? 
¶2 Part I of this iBrief addresses the various aspects of the debate 
concerning the biological testing of indigenous peoples and subsequent 
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patenting of test results. Part II of the iBrief will then discuss the Guayami 
and Hagahai patents, which have largely fueled this debate. Finally, the last 
part of the paper will focus on a much narrower and often overlooked issue. 
That is, what are the responsibilities of the U.S. Patent and Trademark 
Office (USPTO) to monitor these ethically questionable patent applications?  
I. THE DEBATE 
¶3 The rush to patent genome sequences2 did not start with the DNA 
testing of indigenous peoples. Nor is the public unease with this sort of 
intellectual property new. In fact, as early as 1980, the U.S. Supreme Court 
declared that the patenting of living micro-organisms was permissible under 
U.S. patent laws.3 There has been a surge in what some scholars have 
referred to as “hyperownership,” a term that refers to the international 
movement to “own or control access to the subcellular genetic sequences 
that direct the structure and characteristics of all living things, or, in popular 
usage, nature’s or God’s blueprints for life.”4 The U.S. has been the leader 
in this trend, “extending patent protection to a wide and increasing array of 
genetic material.”5 By the middle of the year 2000, “the [USPTO] had 
issued over six thousand patents on full-length genes isolated from living 
organisms and were considering over twenty thousand gene-related patent 
applications.”6  
¶4 The legal world has recently addressed human genome sequences 
as a source of intellectual property. Debate has arisen regarding whether 
doctors have a right to the research and subsequent patenting of a patient’s 
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“discarded” biological tissue.7 Also, a huge uproar ensued when it was 
discovered that research physicians patented and commercialized a test for 
Canavan’s disease from the bequeathed biological material of patients who 
donated their biological tissue under the belief that it would be used solely 
to help diseased patients.8 Critics have noted that “[p]atient lawsuits seeking 
recovery of a researcher’s patent profits, from patents involving the 
patient’s genetic material . . . will likely recur.”9 Furthermore, “[a]bsent 
legislative intervention to compensate patients, they have reduced 
incentives to donate their genetic material to further scientific research.”10 
The DNA collection from indigenous groups, however, has created a new, 
much more ethically-charged, dialogue to this decade-old debate. 
A. The Human Genome Diversity Project  
¶5 The Human Genome Diversity Project (HGDP) served as the 
catalyst behind the biological testing of indigenous groups. Founded by 
Luigi Luca Cavalli-Sforza, a population geneticist at Stanford University, 
and other U.S. scientists, the HGDP “aims to collect blood, skin, and hair 
samples from hundreds of ethnic groups around the world and use new 
techniques to preserve genetic information indefinitely.”11 The HGDP is 
part of an international movement that wishes to “analyz[e] the structure of 
human DNA and ascertain[] the location of all human genes by mapping 
and sequencing  the human genome.”12 Collection of this information is of 
utmost importance to scientists for the following reasons: 
First, thus far the vast majority of detailed research into human 
genetics has been done with Europeans or North Americans of 
European descent, and thus omits the eighty percent of the world’s 
population that is not of European ancestry. It is fundamentally unfair 
to the majority of humanity to describe the human genome without 
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including a representative sample of all humans. Second, studying 
human genetic diversity will help us understand better the workings of 
evolution in humans, including the ways in which culture influences 
evolution. Third, greater knowledge of human genetic diversity will 
improve medicine, both because it will advance the study of those 
genetic diseases found largely in non-European populations, and 
because genetic variation is basic to better understanding a host of 
diseases found in all peoples. Finally, studying human diversity will 
help us uncover our shared human history. Genetic results, when 
interpreted along with evidence from anthropology, archaeology, 
history, linguistics, and other fields, will help map human migrations 
and expansions in prehistoric times.13
¶6 HGDP advocates also point out that ethnic groups that in the past 
have been subjects of genetic testing have welcomed the research. In 
particular, the Old Order Amish were very concerned about mental health 
issues within their ethnic group and were thus very cooperative with genetic 
researchers.14 Like indigenous populations, “this group is located within a 
small geographic location” and “is both genetically and culturally 
homogenous.”15 The HGDP advocates that participation from all groups is 
essential because “[r]esearch in human genetics is by its nature collective 
research. One person’s genome is only revealing in the context of the 
genomes of others.”16 The individual, the group, and the world all benefit 
from this information. For instance:  
Research into a family or a group of families with a high incidence of 
a disease may reveal that those families are more likely than average to 
carry a "flawed" allele of a gene. That information necessarily has 
implications for every family member, whether she took part in the 
research or not. She knows that she, her parents, her children, and her 
other relatives are at a higher risk for this genetic disorder. She will 
often learn that she can be tested for the disease allele—and so will 
everyone else, including her potential employers and insurers. The 
same dynamic is at work in ethnic groups. The fact that sickle cell 
anemia, for example, is much more common among African-
Americans than among European-Americans necessarily provides 
some probabilistic information about African-Americans who did not 
                                                     
13 Henry T. Greely, Symposium: International Health Law, The Control of 
Genetic Research: Involving the “Groups Between,” 33 HOUS. L. REV. 1397, 
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14 Id. at 1409. 
15 Id.  
16 Id. at 1409-10. 
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take part in the genetic tests. Information about groups has 
implications for all the members of those groups.17
B. Indigenous Peoples 
¶7 Indigenous populations have seen the seemingly commendable 
goals of the HGDP in a different light. Although the project’s goals suggest 
that “hundreds of ethnic groups” will be tested, the result has been that 
“peoples to be investigated are very small indigenous groups chosen in part 
because of their endangered situation.”18 Many groups view the project as a 
new type of “biocolonialism.”19  Isolated indigenous groups have become 
an ever-limited and rare “source” for the research community.20 Members 
of indigenous groups loathe this characterization and feel exploited for their 
biological resources, recognizing that “the presence of company scientists 
on medical teams—drawing blood as they provided services—represented 
the growing corporate interest in their genes.”21   
¶8 Indigenous groups also resent that their tribes have yet to reap any 
benefit for such invasive testing and have begun to “demand equitable 
compensation.”22 Equitable compensation could be given in the simplest 
form, such as money, or it could just mean that the results of the testing 
benefit the community from which samples were taken. However, neither of 
these forms of compensation is being used. This is largely due to the fact 
that the original goals of the HGDP were indifferent to benefiting the 
subjects of the test. The HGDP began its research with a purely scientific 
focus, stating that “[t]he purpose of the research is ultimately to add to the 
body of scientific knowledge without focusing on the needs of a specific 
community.”23 The subjects of the tests are only considered “necessary to 
provide data, and [are] rarely involved in the research development.”24 
Biomedical results were not meant to be used for, or returned to, the 
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JURIMETRICS J. 121, 127 (2002). 
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J.L. MED. & ETHICS (forthcoming Spring 2006) (manuscript at 11, on file with 
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21 Nelkin, supra note 19, at 127.  
22 Id. 
23 Laura Arbour & Doris Cook, DNA on Loan: Issues to Consider when 
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COMMUNITY GENETICS 3 Vol. 319, (2006), available at 
https://courses.washington.edu/phg580/readings/CMG319%252Epdf.pdf.  
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participants.25 In fact, the individual subjects who participated in the 
research were kept anonymous.26  
¶9 Finally, there is concern as to whether indigenous populations, as 
groups, have any rights or liberties at all to stand against the biological 
testing being conducted. Under American jurisprudence, group rights “are 
generally ignored.”27 The genetic testing of indigenous groups, however, 
raises many group issues because the results of the tests often present very 
specific information about the “ill health” of the entire tribe, which can 
cause panic and fear within the group, as well as bestow upon the entire 
group a certain “stigmatization” that can lead to “discrimination by third 
parties, who act on the prejudices and predictions that this information may 
arouse.”28 Also, many of these groups believe that their genetic materials 
“hold traditional and spiritual significance.”29 A Native American 
geneticist, Dr. Frank Dukapoo, has stated that “[f]or an Indian, it’s not just 
DNA, it’s part of a person, it is sacred, with deep religious significance. It is 
part of the essence of a person.”30  
¶10 This opposition was not anticipated by HGDP scientists.31 
Researchers never foresaw that their work, which they believed would 
benefit everyone in the world in some sense, would raise such ethical issues. 
Although researchers stated that the HGDP would be carried out in the 
general “interests” of indigenous peoples (i.e. it would “immortalize 
vanishing peoples”), it appears as though those “interests” had nothing to do 
with the actual desires of the research subjects.32 Furthermore, “[t]he 
research became a lightning rod for broader concerns about the exploitation 
of developing countries and their resources.”33 The scientific goals of the 
HGDP have been muddled with ethically-loaded questions such as whether 
“the blood taken for this research [was] intended for the purpose of 
improving health or for the purpose of patents and profits.”34 HGDP 
scientists have lost sight of the deeper implications of their work, and 
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“critics believe the research [is] only exploiting indigenous people, 
intervening in their heritage, families, communities, and nations.”35 
II. INTELLECTUAL PROPERTY OVER DATA COLLECTED 
¶11 The USPTO, despite the erupting public controversy, has actually 
encouraged “patents on newly discovered, naturally occurring genes, DNA 
fragments, proteins, and other biochemicals in contravention of long 
established principles of patent law.”36 The USPTO’s Director of 
Biotechnology Examination, John Doll, declared that genetic and DNA 
sequencing should be patented for the following reasons:  
Without the incentive of patents, there would be less investment in 
DNA research, and scientists might not disclose their new DNA 
products to the public. Issuance of patents to such products not only 
results in the dissemination of technological information to the 
scientific community for use as a basis for further research, but also 
stimulates investment in the research, development, and 
commercialization of new biologics. It is only with the patenting of 
DNA technology that some companies, particularly small ones, can 
raise sufficient venture capital to bring beneficial products to the 
marketplace or fund further research. A strong U.S. patent system is 
critical for the continued development and dissemination to the public 
of information on DNA sequence elements.37  
¶12 Critics of this approach, however, demand “an explanation as to 
how chemicals found in the human body can be ‘inventions’ under the 
positive law of patents.”38 Clearly a patent application involving the human 
body varies greatly from, say, patent applications involving software or an 
electronic device. Currently, however, the USPTO does not demand 
separate patent application requirements. 
¶13 Two U.S. patents, in particular, shed light on the need for 
government involvement in curbing patent applications. The first effort to 
patent the genetic sequences revealed from the testing of indigenous groups 
was the Guayami patent. A Guayami woman, who belongs to an indigenous 
group in Panama, was said to have been “illiterate and unschooled” yet 
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allegedly gave “‘informed oral consent’ to the research, even though neither 
the tribe nor the woman knew anything about the development of the cell 
line or the patent application.”39 This patent application was “filed on 
behalf of the Department of Commerce, published as PCT application 
WO92/08784 on May 29, 1992 and directed to ‘Human T-Lymphotropic 
Virus Type II from Guayami Indians in Panama.’”40  
¶14 As a result of the patent application, the President of the Guayami 
General Congress wrote a letter to the U.S. Secretary of Commerce.41 First, 
the letter “demand[ed] that the application be withdrawn because it had 
been made without consultation with the Guayami community or its 
traditional organizations.”42 Second, the letter asserted that “this is not an 
invention but rather a discovery of an antibody which is part of the blood of 
a Guayami woman.”43 The letter also queried what, if any, benefits the 
Guayami people would gain from the proposed patent application.44  As a 
result of this protest from the Guayami leadership as well as from the Rural 
Advancement Foundation International (RAFI) and numerous public 
interest groups, the patent was withdrawn.45  
¶15 The United Nations (UN) also responded to the Guayami patent 
with a “Draft Declaration on the Rights of Indigenous Peoples . . . including 
human genetic materials as cultural property that indigenous populations are 
entitled to control.”46 The UN supported a view, as taken up by many 
protestors, that individuals should have property rights in their biological 
material and should not be forced to comply with the whims of researchers 
when it comes to the human body.47  
¶16 In response to, and slightly rejecting, the UN’s stance that 
indigenous people should have control over their genetic material, Henry 
                                                     
39 David E. Winickoff, Governing Population Genomics: Law, Bioethics, and 
Biopolitics in Three Case Studies, 43 JURIMETRICS J. 187, 200 (2003). 
(examining three case studies as exemplary of changes in population genomics, 
including “the Human Genome Diversity Project, Iceland’s Health Sector 
Database, and ‘Clinical Genomics’ as defined by the Beth Israel-Ardais 
collaboration”). 
40 Kate H. Murashige, Patent Protection for Biotechnology, 382 PLI/PAT 473, 
476 (1994) (commenting on the environmental and socioeconomic impact of 
biotechnology “inventions”/patents).  
41 Id. 
42 Id.  
43 Id. (quoting the actual letter). 
44 Id.  
45 Id. See also Alternative Law Forum—TRIPS, Indigenous Knowledge and the 
Bio-rush, http://altlawforum.org/PUBLICATIONS/document.2004-12-
18.1352831511 (last visited May 11, 2006). 
46 Demaine & Fellmeth, supra note 36, at 438. 
47 Id.  
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Greely, a Stanford Law professor as well as chair of an ethics subcommittee 
for HGDP, protested that “the idea that the U.S. government owns the 
person or his genetic material is absolute rubbish . . . . [T]he donors 
involved can continue, obviously, to use their own DNA to run their 
bodies.”48 Greely believes that once separated from the body, the genetic 
material of indigenous people no longer shares a relationship with the body 
that it was taken from. This view does not assuage concerns regarding the 
“prevalent popular belief that ownership of another person’s genetic 
material invades that person’s privacy; violates his or her bodily integrity, 
often for purposes of economic exploitation; and offends his or her human 
dignity.”49 
¶17 The second controversial claim for intellectual property over an 
indigenous person’s biological material concerns the Hagahai50 patent. 
Here, biomedical researchers successfully “patented the T-lymphotrophic 
virus found in blood of the Hagahai people in Papua New Guinea, believing 
that it could be developed into a diagnostic tool or vaccine for certain types 
of leukemia.”51 The scientists who filed the Hagahai patent claimed to have 
“negotiated a profit-sharing agreement with the Hagahai, a tribe that had 
had no contact with outsiders until 1984, when some tribe members sought 
help for an illness that afflicted the group.”52 Public interest groups were 
outraged. RAFI described the incident as an egregious act of “biopiracy” 
and human “bioprospecting.”53  
¶18 Despite the public outcry, the USPTO granted the application for 
the Hagahai patent to the National Institute of Health (NIH). The patent 
application apparently met the congressionally established “invention” 
requirement.54 The patent application read as follows: 
                                                     
48 Id. 
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50 Patricia A. Lacy, Gene Patenting: Universal Heritage vs. Reward for Human 
Effort, 77 OR. L. REV. 783, 794–95 (1998) (“The Hagahai are a 260-member, 
hunter-horticulturist group which first made sustained contact with government 
and missionary workers in 1984. The Hagahai are of particular interest to the 
NIH because tribe members carry the gene that predisposes humans to leukemia, 
yet they do not manifest symptoms of the illness.”)  
51 Winickoff, supra note 39, at 201. 
52Id. 
53Id. 
54 Lacy, supra note 50, at 796 (“The U.S. Constitution establishes the basis for 
protecting invention in the United States: ‘To promote the Progress of Science 
and useful Arts, by securing for limited Times to Authors and Inventors the 
exclusive Right to their respective Writings and Discoveries.’  Patent law has 
interpreted the framers’ use of ‘Discoveries’ to refer to ‘invention,’ as in 
discoveries requiring human innovation. More recently, biotechnology has 
blurred the distinction between ‘discovery’ and ‘invention.’”) 
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[T]he present invention relates to a vaccine for humans against 
infection with and diseases caused by HTLV-I (Human T-
Lymphotropic Virus) and related viruses comprising a non-infectious 
antigenic portion of the PNG-1 variant, in an amount sufficient to 
induce immunity against said infection and disease, and a 
pharmaceutically acceptable carrier.55
¶19 It appears as though biological material taken from human beings 
can, in fact, constitute a patentable invention. In fact, the Supreme Court 
laid out the lax test for patenting biological material in Diamond v. 
Chakrabarty56 where the majority supported the notion that “anything under 
the sun that is made by man” constitutes patentable subject matter as long as 
there is a “human-made aspect” to it.57 In the end, the Hagahai patent 
produced little financial award for its owners, and the rights to the patent 
were abandoned.58 
III. THE RESPONSIBILITIES OF THE U.S. PATENT OFFICE 
¶20 Although the patenting of biological resources has existed for the 
last ten years, the USPTO has failed to modify how it reviews patents 
involving genetic resources. Scholars currently believe there is virtually no 
review at all.59 U.S. Senator Mark O. Hatfield has voiced his concern for 
such inaction, noting that “the underlying ethical decisions related to the 
developments in biomedicine transcend our . . . patent laws,” and not only 
do they transcend our patent laws, but “they transcend our national 
borders,” as is the case with the biological research of indigenous peoples.60 
Researchers are rushing to patent human genome sequences. Consider the 
fact that on just one day “the National Institute of Health (NIH) filed patent 
applications on 2300 gene fragments,” which is surprising considering that 
“the Patent and Trademark Office (PTO), aided only by centuries old patent 
law, could offer such protection.”61 One would think that the patenting of 
genetic material extracted from human beings “is more than a technical or 
legal question of patentability.”62 To date, it looks like the USPTO has 
failed to implement any type of formal ethical review process of patent 
applications. The floodgates remain open for patent application regarding 
                                                     
55 Lacy, supra note 50, at 794 (quoting U.S. Patent No. 5,397,696 (filed Aug. 12, 
1991). 
56 447 U.S. 303. 
57 Id. at 309 n.3. 
58 Winickoff, supra note 39, at 200. 
59 Email from Arti Rai, Professor of Law, Duke University School of Law (Feb. 
7, 2006) (on file with author). 
60 Mark O. Hatfield, From Microbe to Man, 1 ANIMAL L. 5, 6 (1995). 
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genes from the human body. As a result of this failure, Senator Hatfield 
advocated the following to Congress:  
The USPTO has no way of dealing with the various moral, 
international, economic and environmental questions which arise from 
the patenting of human genes, cells, and organs, or the patenting of 
genetically engineered animals. Careful consideration and examination 
has not taken place in the case of the genetic alteration and patenting 
of human genes and body parts, or in the case of the creation and 
patenting of transgenic animals. In each session of Congress since 
1987, I have introduced legislation to place a moratorium on allowing 
the Patent and Trademark Office to issue patents on living 
organisms.63
¶21 Some groups, however, are taking action, including the HGDP. In 
response to the public dismay at the Hagahai and Guayami patent 
applications, the North American Regional Committee of the Diversity 
Project of the HGDP developed a “Proposed Model Ethical Protocol (MEP) 
For Collecting DNA Samples.”64  Although nothing like this has been 
implemented by the USPTO, the HGDP’s own efforts have helped to curb 
patent applications in the U.S. and address some of the ethical issues at 
stake. The MEP has inserted a new ideology into their work, stating that 
“the research must ‘not only [do] no harm to the participating communities, 
but, where possible, bring them benefits.’”65 This has been a shift from 
what much of the public considered as a dispassionate view on research 
subjects. Further, the MEP states that the HGDP itself “‘will not profit from 
any commercial uses of samples it gathers or knowledge derived from those 
samples’ and that the HGDP ‘has vowed to ensure that, should commercial 
products be developed as a result of the HGDP’s collections, a fair share of 
the financial rewards shall return to the sampled populations.’”66 Dr. David 
E. Winickoff suggests three possible ways in which these requirements can 
be satisfied as set out by the Protocol:  
(1) researchers could not “make use of the HGDP’s samples or data in 
a patent application or a commercial product without the express 
written permission of the sampled populations involved, . .  subject to 
whatever conditions they impose for that permission;” (2) “anyone 
making commercial use of the HGDP’s samples would pay a set 
percentage royalty . . . for the benefit of the sampled populations;” and 
(3) “anyone making commercial use of the HGDP’s samples or data 
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64 Winickoff, supra note 39, at 197. 
65 Id. at 200 (quoting Symposium, Proposed Model Ethical Protocol for 
Collecting DNA Samples, 33 HOUS. L. REV. 1431, 1436 (1997)). 
66 Id. at 200-01 (quoting Symposium, Proposed Model Ethical Protocol for 
Collecting DNA Samples, 33 HOUS. L. REV. 1431, 1466-67 (1997)). 
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would have to negotiate a reasonable financial payment with a trustee 
for the sampled populations, with the proceeds for the population’s 
benefit."67  
¶22 Although the HGDP has not vowed to stop its research altogether, it 
does aim to “stick to science”—that is, it is making it clear that it is not in it 
for its profit potential. However, this MEP does not rule out commercial 
uses of the research. In essence, the HGDP is trying to rid itself of the moral 
implications of profiting from collected biological material. This act 
essentially places an even greater responsibility on the USPTO. With the 
HGDP’s MEP washing its hands clean of the possible uses of its research, 
the USPTO now stands even more alone as a potential barrier to patents 
involving the genetic materials of indigenous peoples. In its MEP, the 
HGDP also agrees that if profits do result from the research that it will 
attempt to return some of those financial gains to indigenous groups. This 
MEP, however, does not come close to addressing some of the “property” 
issues at stake (i.e. is there a property interest either individually or 
collectively in  human genetic material at all?). Nor does it consider the 
sacred value that many indigenous groups place on the biological matter 
which is being taken from them. 
¶23 The USPTO has yet to implement its own Model Ethical Protocol 
or any procedure of “ethical review.”68 One scholar, Nuno Pires de 
Carvalho, proposed a rather novel “re-engineering” of the law concerning 
biotechnology patents.69 In particular, he suggests that the government 
should implement, as a requisite for patentability, the “requirement that 
applicants for patents in the field of biotechnology disclose the source of the 
genetic resources eventually used as raw materials or tools in the inventive 
activity”70 (“Carvalho Requirement”).  He also suggests that evidence, if 
any, of informed consent from the research subjects be included in the 
application.71 However, what should constitute proper informed consent 
and how scientists should go about getting it is still very controversial.72 
¶24 The Carvalho Requirement has already been integrated into two 
foreign statutes: “Andean Decision No. 391 of August 16, 1996, which 
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68 Rai, supra note 59. 
69 Nuno Pires de Carvalho, Requiring Disclosure of the Origin of Genetic 
Resources and Prior Informed Consent in Patent Applications without 
Infringing the TRIPS Agreement: The Problem and the Solution, 2 WASH. U. 
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70 Id. at 374. 
71 Id.  
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establishes a Common Regime on Access to Genetic Resources; and the 
Biodiversity Law (No. 7788) of Costa Rica enacted May 27, 1998.”73 Both 
of these laws require patent applicants to describe, in detail, the following: 
“information concerning the origin of the genetic resource in question and 
some proof of prior informed consent from government authorities as well 
as traditional knowledge holders, whenever the resource will be obtained 
through their technical knowledge.”74 Furthermore, the Carvalho 
Requirement is expected to be proposed to the World Trade Organization 
(WTO) and the World Intellectual Property Organization (WIPO), and there 
has already been a proposed amendment to Article 29 of the TRIPS 
Agreement.75  
¶25 It appears as though the international community has started to 
recognize the lack of oversight in biological patents. For instance, when the 
WIPO Standing Committee on the Law of Patents convened in 1999, 
Colombia proposed some very ethically-conscious language to be included 
in the proposed Patent Law Treaty: 
 1. All industrial property protection shall guarantee the protection of 
the country’s biological and genetic heritage. Consequently, the grant 
of patents or registrations that relate to elements of that heritage shall 
be subject to their having been acquired legally.  
2. Every document shall specify the registration number of the contract 
affording access to genetic resources and a copy thereof where the 
goods or services for which protection is sought have been 
manufactured or developed from genetic resources, or products 
thereof, of which one of the member countries is the country of 
origin.76
¶26 Carvalho considers the Colombian proposal to be a more 
“substantive” requirement than his proposal in that the Carvalho 
Requirement “concerns information that does not relate directly to the 
activity of inventing” and it “does not characterize the invention itself.”77 
Rather, he refers to the Carvalho Requirement as an “accessory” not unlike 
other requirements found within a patent application such as “where the 
invention was invented as part of the work performed under a contract with 
the government” and the applicant must provide “any document containing 
a statement which indicates any government licensing rights in the 
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invention and identifies the government contract.”78 What both the 
Carvalho Requirement and the Colombian proposal share in common, 
however, is that each impose a “condition on patentability.”79 And as with 
any imposed condition, both of these proposals would make it more 
challenging for researchers to assert intellectual property rights over 
biological material collected from indigenous populations. 
IV. CONCLUSION 
¶27 With the advent of a heightened international consciousness 
concerning the ethical implications of collecting the DNA of indigenous 
peoples, it would seem as though the USPTO would have taken some sort 
of step by now to modify the patent application process. Unfortunately, no 
changes have been made. Rather, the USPTO has approved of what some 
see as a “patent on a foreign citizen.”80 This iBrief, by outlining the multi-
faceted debate on this issue as well as by demonstrating how other countries 
have chosen to revise their patent application process, hopes to increase 
public awareness and contribute to the patent reform movement concerning 
human biological material. 
¶28 The above proposals offer some guidance as to how the U.S. might 
finally implement a procedure of ethical review when faced with biological 
patents.  Even minimal “accessory” changes to the U.S. patent application 
would create a heightened system of awareness as to the activities being 
conducted behind the veil of the patent application. Also, they put a burden 
on the patent applicant herself. Hopefully, the USPTO can start to move 
towards a more active role in curbing ethically-questionable patent 
applications, so that not “anything under the sun that is made by man”81 is 
patentable, especially when it involves the sacred genetic elements that 
many indigenous groups believe make up the essence of who they are as 
people. 
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